Markets
OrbiMed Closes Fifth Healthcare Fund
|
OrbiMed Advisors has closed its OrbiMed Private Investments V with just over $735 million, including $36 million from the general partner. Fund V will invest in all stages and sectors of the healthcare industry, with a focus on biopharmaceutical, medical device and diagnostics companies in North American and Europe. Investors in the fund include some of the largest endowments, foundations, sovereign wealth funds and financial institutions globally. OrbiMed Advisors is an long active investor in equity private placements into emerging growth biotechs and medical device companies. Recent investments include Exact Sciences Corp (EXAS), ADADIA Pharmaceuticals (ACAD) and Aerocrine AB (AEROB:SS).


